- Home
- AG vs SLNO Comparison
AG vs SLNO Comparison
Compare AG & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- SLNO
- Stock Information
- Founded
- AG 1979
- SLNO 1999
- Country
- AG Canada
- SLNO United States
- Employees
- AG N/A
- SLNO N/A
- Industry
- AG Precious Metals
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AG Basic Materials
- SLNO Health Care
- Exchange
- AG Nasdaq
- SLNO Nasdaq
- Market Cap
- AG 4.0B
- SLNO 3.8B
- IPO Year
- AG N/A
- SLNO 2014
- Fundamental
- Price
- AG $10.05
- SLNO $50.98
- Analyst Decision
- AG Strong Buy
- SLNO Strong Buy
- Analyst Count
- AG 3
- SLNO 10
- Target Price
- AG $10.67
- SLNO $112.50
- AVG Volume (30 Days)
- AG 20.8M
- SLNO 1.8M
- Earning Date
- AG 11-06-2025
- SLNO 11-05-2025
- Dividend Yield
- AG 0.20%
- SLNO N/A
- EPS Growth
- AG N/A
- SLNO N/A
- EPS
- AG 0.04
- SLNO N/A
- Revenue
- AG $826,595,000.00
- SLNO $32,656,999.00
- Revenue This Year
- AG $91.40
- SLNO N/A
- Revenue Next Year
- AG N/A
- SLNO $181.85
- P/E Ratio
- AG $262.57
- SLNO N/A
- Revenue Growth
- AG 61.34
- SLNO N/A
- 52 Week Low
- AG $5.09
- SLNO $41.50
- 52 Week High
- AG $10.90
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- AG 59.12
- SLNO 25.29
- Support Level
- AG $9.06
- SLNO $48.91
- Resistance Level
- AG $10.90
- SLNO $72.99
- Average True Range (ATR)
- AG 0.51
- SLNO 4.25
- MACD
- AG 0.10
- SLNO -1.53
- Stochastic Oscillator
- AG 58.13
- SLNO 8.62
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.